Testing a new injectable treatment for chronic hepatitis B

Plain-English translation of NCT07389044 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

This is one of the first times this treatment has been tested in people.

What is this trial?

This is an early-stage trial testing a new medication called that is given as a subcutaneous injection (a shot under the skin). The study will first give the treatment to healthy volunteers to make sure it is safe, and then test it in people who have been diagnosed with chronic hepatitis B. Researchers want to understand how the medication works in the body, what side effects it might cause, and whether it can help fight the hepatitis B virus.

Chronic hepatitis B is a serious viral infection that affects the liver and can lead to long-term complications. This trial exists to see if this new injectable medication offers a safe and effective treatment option for people living with this condition.

Do you qualify?

You likely qualify if…

you are between 18 and 70 years old
you are willing to receive subcutaneous injections and have a suitable injection site on your body
you are able and willing to give written informed consent to participate
if you are of childbearing potential, you are not pregnant or breastfeeding and agree to use effective birth control during the study

You likely don't qualify if…

you have a serious allergy or severe reaction to medications
you have any active viral infections such as hepatitis A, B, C, or HIV
you have had major surgery requiring general anesthesia in the last 12 weeks or expect to have one during the study
you are currently taking prescription or over-the-counter medications (including vitamins or herbal supplements) that cannot be stopped before the study
you have a history of cancer (except non-melanoma skin cancer removed more than a year ago)

What participation looks like

The trial has two main parts. Healthy volunteers in Part A will receive a single injection and then return for follow-up visits over 28 days to check for side effects and how the medication is processed by their body. People with chronic hepatitis B in Part B will receive weekly injections for 4 weeks, with follow-up visits over the next 6 weeks. All participants will have blood tests and physical exams to monitor their safety and the medication's effects.

AI-generated summary from trial data · Jul 5, 2026 · Not medical advice

Trial locations(2 sites)

Moldova

Arensia Exploratory Medicine Chisinau, Chisinau

New Zealand

New Zealand Clinical Research, Auckland